医学
过敏反应
变应原免疫治疗
过敏原
过敏
免疫学
哮喘
过敏反应
免疫疗法
脱敏(药物)
皮肤病科
内科学
免疫系统
受体
作者
Yashu Dhamija,Tolly Epstein,David I. Bernstein
标识
DOI:10.1016/j.iac.2021.09.012
摘要
Subcutaneous allergen immunotherapy (SCIT) is a proven treatment of allergic rhinitis, asthma, atopic dermatitis, and prevention of Hymenoptera venom anaphylaxis. The known benefit of SCIT, however, must be considered in each patient relative to the potential risks of systemic allergic reactions (SRs). A mean of 1 SR per 1000 injection visits (0.1%) was estimated to occur between 2008 and 2018. Life-threatening anaphylactic events are estimated to occur in 1/160,000 injection visits. The factors that contribute to SRs and fatal reactions (FRs) are reviewed. Risk management strategies are proposed to prevent and decrease future SCIT associated with SRs, anaphylaxis, and FR.
科研通智能强力驱动
Strongly Powered by AbleSci AI